Abby Hardy, Author at BioTuesdays

Feature

Micron developing microneedle technology for self-administration of vaccines and therapeutics

Closely-held Micron Biomedical is developing a dissolvable microneedle-based technology that could enable self-administration of vaccines and therapeutics.

November 3, 2020

Developments

Titan Pharma completes debt settlement with Molteni and Horizon; acquisition of JT-09

Titan Pharmaceuticals (NASDAQ:TTNP) settled all of its debt obligations with Molteni & C. dei F.lli Alitti Società di Esercizio and Horizon Credit, as well as the acquisition of JT Pharmaceuticals’ JT-09. Completion...

November 2, 2020

Developments

Zucara Expands ZT-01 Development to Type 2 Diabetes

Closely-held Zucara Therapeutics is expanding the development of ZT-01, which is currently in a Phase 1 trial for the prevention of insulin-induced hypoglycemia in patients with Type 1 Diabetes...

November 2, 2020

Developments

Cerevel doses first patients in three Phase 3 Parkinson’s disease trials

Cerevel Therapeutics (NASDAQ:CERE) dosed the first patients in each of its three Phase 3 trials evaluating tavapadon for the treatment of Parkinson’s disease (PD). Tavapadon is an oral, once-daily partial agonist...

October 30, 2020

Developments

Humanigen reports first patient dosed with lenzilumab in NIH COVID-19 trial

Humanigen (NASDAQ:HGEN) reported that the National Institutes of Health (NIH) has dosed the first hospitalized COVID-19 patient with lenzilumab. Lenzilumab is an antibody that targets granulocyte-macrophage colony...

October 29, 2020

Developments

BioLineRx initiates Phase 2 first-line metastatic pancreatic cancer trial

BioLineRx (NASDAQ:BLRX) launched a Phase 2 trial evaluating motixafortide, in combination with cemiplimab and standard-of-care chemotherapy, in first-line metastatic pancreatic ductal adenocarcinoma (PDAC)...

October 29, 2020

Developments

MediWound completes enrollment in Phase 3 pediatric burn study

MediWound (NASDAQ:MDWD) completed enrollment in a Phase 3 study evaluating NexoBrid for the treatment of burns in patients 18 years of age and younger. NexoBrid is a topically administered biological product that...

October 29, 2020

Developments

IntelGenx inks binding LOI with Heritage for cannabis filmstrip supply

IntelGenx (TSXV:IGX; OTCQB:IGXT) signed a binding letter of intent (LOI) with Heritage Cannabis (CSE:CANN; OTCQX:HERTF) for the supply of CBD-containing filmstrip products for the Canadian and Australian markets. Under...

October 29, 2020

Developments

Titan Pharma to acquire JT-09 to develop ProNeura-based chronic pruritus treatment

Titan Pharmaceuticals (NASDAQ:TTNP) inked an agreement to acquire JT Pharmaceuticals’ kappa opioid agonist peptide, JT-09, for use in combination with Titan’s ProNeura long-term, continuous drug delivery technology, for...

October 28, 2020

Developments

Prevail Therapeutics gets FDA fast track designation for Gaucher disease

Prevail Therapeutics’ (NASDAQ:PRVL) PR001 received FDA fast track designation for the treatment of neuronopathic Gaucher disease. Gaucher disease is a lysosomal storage disorder caused by mutations in the...

October 27, 2020

Author - Abby Hardy

Micron developing microneedle technology for self-administration of vaccines and therapeutics

Titan Pharma completes debt settlement with Molteni and Horizon; acquisition of JT-09

Zucara Expands ZT-01 Development to Type 2 Diabetes

Cerevel doses first patients in three Phase 3 Parkinson’s disease trials

Humanigen reports first patient dosed with lenzilumab in NIH COVID-19 trial

BioLineRx initiates Phase 2 first-line metastatic pancreatic cancer trial

MediWound completes enrollment in Phase 3 pediatric burn study

IntelGenx inks binding LOI with Heritage for cannabis filmstrip supply

Titan Pharma to acquire JT-09 to develop ProNeura-based chronic pruritus treatment

Prevail Therapeutics gets FDA fast track designation for Gaucher disease

Subscribe